Xu Dingtao, Wang Xinyu, Zhou Dehua
Department of Anesthesia and Perioperative Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China.
Department of Thyroid, Breast and Vascular Surgery, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China.
ACS Omega. 2023 Dec 12;8(51):49158-49164. doi: 10.1021/acsomega.3c07287. eCollection 2023 Dec 26.
In order to address the ongoing debate surrounding the potential link between COVID-19 and thyroid cancer, our study was specifically designed to investigate the association between these two factors. We acquired summary data from a genome-wide association study (GWAS) concerning COVID-19 susceptibility and severity of COVID-19 in the European population, with a focus on their relationship with thyroid cancer. We applied three distinct methodologies to evaluate the causality between COVID-19 and thyroid cancer, employing Mendelian randomization (MR)-Egger, weighted median (WM), and inverse variance-weighted (IVW) approaches. Furthermore, we utilized a variety of techniques to assess pleiotropy and heterogeneity, including the MR-Egger intercept, MR-pleiotropy residual sum and outlier method (PRESSO), and Cochran's test. The MR analysis revealed associations between the susceptibility of COVID-19 and thyroid cancer (IVW odds ratio [OR]: 2.826, 95% confidence interval [CI]: [0.842, 9.483], = 0.093) as well as between the risk of COVID-19 hospitalization and thyroid cancer (IVW OR: 1.630, 95% CI: [1.050, 2.529], = 0.029). However, the relationship between COVID-19 and the occurrence of severe thyroid cancer cases was less evident (IVW OR: 1.061, 95% CI: [0.575, 1.956], = 0.850). Our sensitivity analyses did not reveal any signs of horizontal pleiotropy or heterogeneity. Our MR study provided compelling evidence supporting a causal connection between the risk of COVID-19 hospitalization and thyroid cancer. Nevertheless, the MR results derived from genetic data do not support a causal link between susceptibility to COVID-19 and the risk of thyroid cancer or between very severe cases of COVID-19 and the risk of thyroid cancer. These findings have significant implications for further investigations into the impact of COVID-19 on health and the etiology of thyroid cancer.
为了解决围绕新冠病毒(COVID-19)与甲状腺癌之间潜在联系的持续争论,我们的研究专门设计用于调查这两个因素之间的关联。我们从一项全基因组关联研究(GWAS)中获取了有关欧洲人群中COVID-19易感性和COVID-19严重程度的汇总数据,重点关注它们与甲状腺癌的关系。我们应用了三种不同的方法来评估COVID-19与甲状腺癌之间的因果关系,采用孟德尔随机化(MR)-Egger法、加权中位数(WM)法和逆方差加权(IVW)法。此外,我们利用了多种技术来评估多效性和异质性,包括MR-Egger截距、MR多效性残差和异常值方法(PRESSO)以及 Cochr an检验。MR分析揭示了COVID-19易感性与甲状腺癌之间的关联(IVW优势比[OR]:2.826,95%置信区间[CI]:[0.842,9.483],P = 0.093)以及COVID-19住院风险与甲状腺癌之间的关联(IVW OR:1.630,95% CI:[1.050,2.529],P = 0.029)。然而,COVID-19与严重甲状腺癌病例发生之间的关系不太明显(IVW OR:1.061,95% CI:[0.575,1.956],P = 0.850)。我们的敏感性分析未发现任何水平多效性或异质性的迹象。我们的MR研究提供了有力证据,支持COVID-19住院风险与甲状腺癌之间存在因果联系。然而,从遗传数据得出的MR结果不支持COVID-19易感性与甲状腺癌风险之间或COVID-19非常严重病例与甲状腺癌风险之间存在因果联系。这些发现对进一步研究COVID-19对健康的影响以及甲状腺癌的病因具有重要意义。